Abstract
Cytosolic determinations of cathepsin-D (cath-D), urokinase plasminogen activator (uPA) and its specific inhibitor PAI-1 have shown an association with adverse prognosis in breast cancer. Our aim was to study the distribution of these markers in small axillary node-negative breast carcinomas using immunohistochemistry and relate the semiquantitative results to known prognostic factors, the expression of tenascin-C (Tn-C) in invasion border of the tumour and prognosis. All the 158 women (159 tumours) were treated with breast conserving surgery and postoperative radiotherapy. Cytoplasmic immunoreactivity for cath-D was seen in carcinoma cells in 47% and in stromal cells in 44%. Nearly all tumours expressed uPA and PAI-1, which were categorized to cytoplasmic expression in carcinoma cells and diffuse stromal expression and quantified – / + / ++ / +++ and further dichotomized for purposes of analysis. Expression of uPA and PAI-1 in stromal fibroblasts was recorded as – / +. Cytoplasmic and stromal cell cath-D contents were associated with grade, proliferation, Tn-C expression in the tumour invasion border and the development of distant metastasis. In multivariate analysis stromal cath-D proved to be an independent prognostic factor for metastasis. Stromal expression of uPA was associated with an increased risk of local recurrence; otherwise high levels of uPA did not associate with other prognostic factors nor with prognosis. Fibroblastic expression of PAI-1 showed an association with both local and distant disease recurrence. However, no consistent association between the immunohistochemically quantified uPA and PAI-1 and prognosis was found. In conclusion, immunohistochemical determination of cath-D seems to be a viable method to predict a higher risk of metastasis but not local recurrence in small axillary node-negative breast carcinomas.© 1999 Cancer Research Campaign
Keywords: cathepsin-D, uPA, PAI-1, immunohistochemistry, early breast cancer, breast-conserving surgery, metastasis, local recurrence
Full Text
The Full Text of this article is available as a PDF (283.7 KB).
Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Aaltonen M., Lipponen P., Kosma V. M., Aaltomaa S., Syrjänen K. Prognostic value of cathepsin-D expression in female breast cancer. Anticancer Res. 1995 May-Jun;15(3):1033–1037. [PubMed] [Google Scholar]
- Alo' P. L., Visca P., Marci A., Mangoni A., Botti C., Di Tondo U. Expression of fatty acid synthase (FAS) as a predictor of recurrence in stage I breast carcinoma patients. Cancer. 1996 Feb 1;77(3):474–482. doi: 10.1002/(SICI)1097-0142(19960201)77:3<474::AID-CNCR8>3.0.CO;2-K. [DOI] [PubMed] [Google Scholar]
- Armas O. A., Gerald W. L., Lesser M. L., Arroyo C. D., Norton L., Rosen P. P. Immunohistochemical detection of cathepsin D in T2N0M0 breast carcinoma. Am J Surg Pathol. 1994 Feb;18(2):158–166. doi: 10.1097/00000478-199402000-00005. [DOI] [PubMed] [Google Scholar]
- Bernstein L. R., Liotta L. A. Molecular mediators of interactions with extracellular matrix components in metastasis and angiogenesis. Curr Opin Oncol. 1994 Jan;6(1):106–113. doi: 10.1097/00001622-199401000-00015. [DOI] [PubMed] [Google Scholar]
- Bianchi E., Cohen R. L., Dai A., Thor A. T., Shuman M. A., Smith H. S. Immunohistochemical localization of the plasminogen activator inhibitor-1 in breast cancer. Int J Cancer. 1995 Mar 3;60(5):597–603. doi: 10.1002/ijc.2910600505. [DOI] [PubMed] [Google Scholar]
- Bouchet C., Spyratos F., Martin P. M., Hacène K., Gentile A., Oglobine J. Prognostic value of urokinase-type plasminogen activator (uPA) and plasminogen activator inhibitors PAI-1 and PAI-2 in breast carcinomas. Br J Cancer. 1994 Feb;69(2):398–405. doi: 10.1038/bjc.1994.74. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Cardiff R. D. Cathepsin D and breast cancer: useful? Hum Pathol. 1994 Sep;25(9):847–848. doi: 10.1016/0046-8177(94)90001-9. [DOI] [PubMed] [Google Scholar]
- Castiglioni T., Merino M. J., Elsner B., Lah T. T., Sloane B. F., Emmert-Buck M. R. Immunohistochemical analysis of cathepsins D, B, and L in human breast cancer. Hum Pathol. 1994 Sep;25(9):857–862. doi: 10.1016/0046-8177(94)90003-5. [DOI] [PubMed] [Google Scholar]
- Charpin C., Devictor B., Bonnier P., Andrac L., Lavaut M. N., Allasia C., Piana L. Cathepsin D immunocytochemical assays in breast carcinomas: image analysis and correlation to prognostic factors. J Pathol. 1993 Aug;170(4):463–470. doi: 10.1002/path.1711700410. [DOI] [PubMed] [Google Scholar]
- Christensen L., Wiborg Simonsen A. C., Heegaard C. W., Moestrup S. K., Andersen J. A., Andreasen P. A. Immunohistochemical localization of urokinase-type plasminogen activator, type-1 plasminogen-activator inhibitor, urokinase receptor and alpha(2)-macroglobulin receptor in human breast carcinomas. Int J Cancer. 1996 May 16;66(4):441–452. doi: 10.1002/(SICI)1097-0215(19960516)66:4<441::AID-IJC6>3.0.CO;2-W. [DOI] [PubMed] [Google Scholar]
- Costantini V., Sidoni A., Deveglia R., Cazzato O. A., Bellezza G., Ferri I., Bucciarelli E., Nenci G. G. Combined overexpression of urokinase, urokinase receptor, and plasminogen activator inhibitor-1 is associated with breast cancer progression: an immunohistochemical comparison of normal, benign, and malignant breast tissues. Cancer. 1996 Mar 15;77(6):1079–1088. doi: 10.1002/(sici)1097-0142(19960315)77:6<1079::aid-cncr12>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
- Danø K., Andreasen P. A., Grøndahl-Hansen J., Kristensen P., Nielsen L. S., Skriver L. Plasminogen activators, tissue degradation, and cancer. Adv Cancer Res. 1985;44:139–266. doi: 10.1016/s0065-230x(08)60028-7. [DOI] [PubMed] [Google Scholar]
- Domagala W., Striker G., Szadowska A., Dukowicz A., Weber K., Osborn M. Cathepsin D in invasive ductal NOS breast carcinoma as defined by immunohistochemistry. No correlation with survival at 5 years. Am J Pathol. 1992 Nov;141(5):1003–1012. [PMC free article] [PubMed] [Google Scholar]
- Duffy M. J., Brouillet J. P., Reilly D., McDermott E., O'Higgins N., Fennelly J. J., Maudelonde T., Rochefort H. Cathepsin D concentration in breast cancer cytosols: correlation with biochemical, histological, and clinical findings. Clin Chem. 1991 Jan;37(1):101–104. [PubMed] [Google Scholar]
- Duffy M. J., O'Grady P., Devaney D., O'Siorain L., Fennelly J. J., Lijnen H. J. Urokinase-plasminogen activator, a marker for aggressive breast carcinomas. Preliminary report. Cancer. 1988 Aug 1;62(3):531–533. doi: 10.1002/1097-0142(19880801)62:3<531::aid-cncr2820620315>3.0.co;2-b. [DOI] [PubMed] [Google Scholar]
- Duffy M. J., Reilly D., Brouillet J. P., McDermott E. W., Faul C., O'Higgins N., Fennelly J. J., Maudelonde T., Rochefort H. Cathepsin D concentration in breast cancer cytosols: correlation with disease-free interval and overall survival. Clin Chem. 1992 Oct;38(10):2114–2116. [PubMed] [Google Scholar]
- Duffy M. J., Reilly D., O'Sullivan C., O'Higgins N., Fennelly J. J., Andreasen P. Urokinase-plasminogen activator, a new and independent prognostic marker in breast cancer. Cancer Res. 1990 Nov 1;50(21):6827–6829. [PubMed] [Google Scholar]
- Fernö M., Baldetorp B., Borg A., Brouillet J. P., Olsson H., Rochefort H., Sellberg G., Sigurdsson H., Killander D. Cathepsin D, both a prognostic factor and a predictive factor for the effect of adjuvant tamoxifen in breast cancer. South Sweden Breast Cancer Group. Eur J Cancer. 1994;30A(14):2042–2048. doi: 10.1016/0959-8049(94)00307-q. [DOI] [PubMed] [Google Scholar]
- Ferrandina G., Scambia G., Bardelli F., Benedetti Panici P., Mancuso S., Messori A. Relationship between cathepsin-D content and disease-free survival in node-negative breast cancer patients: a meta-analysis. Br J Cancer. 1997;76(5):661–666. doi: 10.1038/bjc.1997.442. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Foekens J. A., Schmitt M., van Putten W. L., Peters H. A., Bontenbal M., Jänicke F., Klijn J. G. Prognostic value of urokinase-type plasminogen activator in 671 primary breast cancer patients. Cancer Res. 1992 Nov 1;52(21):6101–6105. [PubMed] [Google Scholar]
- Foekens J. A., Schmitt M., van Putten W. L., Peters H. A., Kramer M. D., Jänicke F., Klijn J. G. Plasminogen activator inhibitor-1 and prognosis in primary breast cancer. J Clin Oncol. 1994 Aug;12(8):1648–1658. doi: 10.1200/JCO.1994.12.8.1648. [DOI] [PubMed] [Google Scholar]
- Foucré D., Bouchet C., Hacène K., Pourreau-Schneider N., Gentile A., Martin P. M., Desplaces A., Oglobine J. Relationship between cathepsin D, urokinase, and plasminogen activator inhibitors in malignant vs benign breast tumours. Br J Cancer. 1991 Nov;64(5):926–932. doi: 10.1038/bjc.1991.428. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Granata G., Coradini D., Cappelletti V., Di Fronzo G. Prognostic relevance of cathepsin D versus oestrogen receptors in node negative breast cancers. Eur J Cancer. 1991;27(8):970–972. doi: 10.1016/0277-5379(91)90260-k. [DOI] [PubMed] [Google Scholar]
- Grøndahl-Hansen J., Christensen I. J., Rosenquist C., Brünner N., Mouridsen H. T., Danø K., Blichert-Toft M. High levels of urokinase-type plasminogen activator and its inhibitor PAI-1 in cytosolic extracts of breast carcinomas are associated with poor prognosis. Cancer Res. 1993 Jun 1;53(11):2513–2521. [PubMed] [Google Scholar]
- Grøndahl-Hansen J., Hilsenbeck S. G., Christensen I. J., Clark G. M., Osborne C. K., Brünner N. Prognostic significance of PAI-1 and uPA in cytosolic extracts obtained from node-positive breast cancer patients. Breast Cancer Res Treat. 1997 Apr;43(2):153–163. doi: 10.1023/a:1005744914124. [DOI] [PubMed] [Google Scholar]
- Henry J. A., McCarthy A. L., Angus B., Westley B. R., May F. E., Nicholson S., Cairns J., Harris A. L., Horne C. H. Prognostic significance of the estrogen-regulated protein, cathepsin D, in breast cancer. An immunohistochemical study. Cancer. 1990 Jan 15;65(2):265–271. doi: 10.1002/1097-0142(19900115)65:2<265::aid-cncr2820650214>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
- Hofmann R., Lehmer A., Buresch M., Hartung R., Ulm K. Clinical relevance of urokinase plasminogen activator, its receptor, and its inhibitor in patients with renal cell carcinoma. Cancer. 1996 Aug 1;78(3):487–492. doi: 10.1002/(SICI)1097-0142(19960801)78:3<487::AID-CNCR16>3.0.CO;2-V. [DOI] [PubMed] [Google Scholar]
- Isola J., Weitz S., Visakorpi T., Holli K., Shea R., Khabbaz N., Kallioniemi O. P. Cathepsin D expression detected by immunohistochemistry has independent prognostic value in axillary node-negative breast cancer. J Clin Oncol. 1993 Jan;11(1):36–43. doi: 10.1200/JCO.1993.11.1.36. [DOI] [PubMed] [Google Scholar]
- Jahkola T., Toivonen T., Nordling S., von Smitten K., Virtanen I. Expression of tenascin-C in intraductal carcinoma of human breast: relationship to invasion. Eur J Cancer. 1998 Oct;34(11):1687–1692. doi: 10.1016/s0959-8049(98)00215-9. [DOI] [PubMed] [Google Scholar]
- Jahkola T., Toivonen T., Virtanen I., von Smitten K., Nordling S., von Boguslawski K., Haglund C., Nevanlinna H., Blomqvist C. Tenascin-C expression in invasion border of early breast cancer: a predictor of local and distant recurrence. Br J Cancer. 1998 Dec;78(11):1507–1513. doi: 10.1038/bjc.1998.714. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jahkola T., Toivonen T., von Smitten K., Blomqvist C., Virtanen I. Expression of tenascin in invasion border of early breast cancer correlates with higher risk of distant metastasis. Int J Cancer. 1996 Dec 20;69(6):445–447. doi: 10.1002/(SICI)1097-0215(19961220)69:6<445::AID-IJC4>3.0.CO;2-4. [DOI] [PubMed] [Google Scholar]
- Joensuu H., Toikkanen S., Isola J. Stromal cell cathepsin D expression and long-term survival in breast cancer. Br J Cancer. 1995 Jan;71(1):155–159. doi: 10.1038/bjc.1995.32. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Jänicke F., Schmitt M., Pache L., Ulm K., Harbeck N., Höfler H., Graeff H. Urokinase (uPA) and its inhibitor PAI-1 are strong and independent prognostic factors in node-negative breast cancer. Breast Cancer Res Treat. 1993;24(3):195–208. doi: 10.1007/BF01833260. [DOI] [PubMed] [Google Scholar]
- Jänicke F., Schmitt M., Ulm K., Gössner W., Graeff H. Urokinase-type plasminogen activator antigen and early relapse in breast cancer. Lancet. 1989 Oct 28;2(8670):1049–1049. doi: 10.1016/s0140-6736(89)91070-2. [DOI] [PubMed] [Google Scholar]
- Kandalaft P. L., Chang K. L., Ahn C. W., Traweek S. T., Mehta P., Battifora H. Prognostic significance of immunohistochemical analysis of cathepsin D in low-stage breast cancer. Cancer. 1993 May 1;71(9):2756–2763. doi: 10.1002/1097-0142(19930501)71:9<2756::aid-cncr2820710912>3.0.co;2-1. [DOI] [PubMed] [Google Scholar]
- Keski-Oja J., Lohi J., Tuuttila A., Tryggvason K., Vartio T. Proteolytic processing of the 72,000-Da type IV collagenase by urokinase plasminogen activator. Exp Cell Res. 1992 Oct;202(2):471–476. doi: 10.1016/0014-4827(92)90101-d. [DOI] [PubMed] [Google Scholar]
- Kute T. E., Shao Z. M., Sugg N. K., Long R. T., Russell G. B., Case L. D. Cathepsin D as a prognostic indicator for node-negative breast cancer patients using both immunoassays and enzymatic assays. Cancer Res. 1992 Oct 1;52(19):5198–5203. [PubMed] [Google Scholar]
- Liotta L. A., Tryggvason K., Garbisa S., Robey P. G., Abe S. Partial purification and characterization of a neutral protease which cleaves type IV collagen. Biochemistry. 1981 Jan 6;20(1):100–104. doi: 10.1021/bi00504a017. [DOI] [PubMed] [Google Scholar]
- Mulcahy H. E., Duffy M. J., Gibbons D., McCarthy P., Parfrey N. A., O'Donoghue D. P., Sheahan K. Urokinase-type plasminogen activator and outcome in Dukes' B colorectal cancer. Lancet. 1994 Aug 27;344(8922):583–584. doi: 10.1016/s0140-6736(94)91968-2. [DOI] [PubMed] [Google Scholar]
- Namer M., Ramaioli A., Fontana X., Etienne M. C., Héry M., Jourlait A., Milano G., Frenay M., François E., Lapalus F. Prognostic value of total cathepsin D in breast tumors. A possible role in selection of chemoresistant patients. Breast Cancer Res Treat. 1991 Oct;19(2):85–93. doi: 10.1007/BF01980938. [DOI] [PubMed] [Google Scholar]
- O'Donoghue A. E., Poller D. N., Bell J. A., Galea M. H., Elston C. W., Blamey R. W., Ellis I. O. Cathepsin D in primary breast carcinoma: adverse prognosis is associated with expression of cathepsin D in stromal cells. Breast Cancer Res Treat. 1995;33(2):137–145. doi: 10.1007/BF00682721. [DOI] [PubMed] [Google Scholar]
- Pujol P., Maudelonde T., Daures J. P., Rouanet P., Brouillet J. P., Pujol H., Rochefort H. A prospective study of the prognostic value of cathepsin D levels in breast cancer cytosol. Cancer. 1993 Mar 15;71(6):2006–2012. doi: 10.1002/1097-0142(19930315)71:6<2006::aid-cncr2820710614>3.0.co;2-q. [DOI] [PubMed] [Google Scholar]
- Ravdin P. M. Evaluation of cathepsin D as a prognostic factor in breast cancer. Breast Cancer Res Treat. 1993;24(3):219–226. doi: 10.1007/BF01833262. [DOI] [PubMed] [Google Scholar]
- Ravdin P. M., Tandon A. K., Allred D. C., Clark G. M., Fuqua S. A., Hilsenbeck S. H., Chamness G. C., Osborne C. K. Cathepsin D by western blotting and immunohistochemistry: failure to confirm correlations with prognosis in node-negative breast cancer. J Clin Oncol. 1994 Mar;12(3):467–474. doi: 10.1200/JCO.1994.12.3.467. [DOI] [PubMed] [Google Scholar]
- Razumović J. J., Stojković R. R., Petrovecki M., Gamulin S. Correlation of two methods for determination of cathepsin D in breast carcinoma (immunohistochemistry and ELISA in cytosol). Breast Cancer Res Treat. 1997 Apr;43(2):117–122. doi: 10.1023/a:1005789606641. [DOI] [PubMed] [Google Scholar]
- Reilly D., Christensen L., Duch M., Nolan N., Duffy M. J., Andreasen P. A. Type-1 plasminogen activator inhibitor in human breast carcinomas. Int J Cancer. 1992 Jan 21;50(2):208–214. doi: 10.1002/ijc.2910500209. [DOI] [PubMed] [Google Scholar]
- Rochefort H. The prognostic value of cathepsin D in breast cancer. A long road to the clinic. Eur J Cancer. 1996 Jan;32A(1):7–8. doi: 10.1016/0959-8049(95)00637-0. [DOI] [PubMed] [Google Scholar]
- Roger P., Montcourrier P., Maudelonde T., Brouillet J. P., Pages A., Laffargue F., Rochefort H. Cathepsin D immunostaining in paraffin-embedded breast cancer cells and macrophages: correlation with cytosolic assay. Hum Pathol. 1994 Sep;25(9):863–871. doi: 10.1016/0046-8177(94)90004-3. [DOI] [PubMed] [Google Scholar]
- Spyratos F., Martin P. M., Hacène K., Romain S., Andrieu C., Ferrero-Poüs M., Deytieux S., Le Doussal V., Tubiana-Hulin M., Brunet M. Multiparametric prognostic evaluation of biological factors in primary breast cancer. J Natl Cancer Inst. 1992 Aug 19;84(16):1266–1272. doi: 10.1093/jnci/84.16.1266. [DOI] [PubMed] [Google Scholar]
- Spyratos F., Maudelonde T., Brouillet J. P., Brunet M., Defrenne A., Andrieu C., Hacene K., Desplaces A., Rouëssé J., Rochefort H. Cathepsin D: an independent prognostic factor for metastasis of breast cancer. Lancet. 1989 Nov 11;2(8672):1115–1118. doi: 10.1016/s0140-6736(89)91487-6. [DOI] [PubMed] [Google Scholar]
- Tandon A. K., Clark G. M., Chamness G. C., Chirgwin J. M., McGuire W. L. Cathepsin D and prognosis in breast cancer. N Engl J Med. 1990 Feb 1;322(5):297–302. doi: 10.1056/NEJM199002013220504. [DOI] [PubMed] [Google Scholar]
- Thorpe S. M., Rochefort H., Garcia M., Freiss G., Christensen I. J., Khalaf S., Paolucci F., Pau B., Rasmussen B. B., Rose C. Association between high concentrations of Mr 52,000 cathepsin D and poor prognosis in primary human breast cancer. Cancer Res. 1989 Nov 1;49(21):6008–6014. [PubMed] [Google Scholar]
- Têtu B., Brisson J., Côté C., Brisson S., Potvin D., Roberge N. Prognostic significance of cathepsin-D expression in node-positive breast carcinoma: an immunohistochemical study. Int J Cancer. 1993 Sep 30;55(3):429–435. doi: 10.1002/ijc.2910550318. [DOI] [PubMed] [Google Scholar]
- Westley B. R., May F. E. Cathepsin D and breast cancer. Eur J Cancer. 1996 Jan;32A(1):15–24. doi: 10.1016/0959-8049(95)00530-7. [DOI] [PubMed] [Google Scholar]
- Winstanley J. H., Leinster S. J., Cooke T. G., Westley B. R., Platt-Higgins A. M., Rudland P. S. Prognostic significance of cathepsin-D in patients with breast cancer. Br J Cancer. 1993 Apr;67(4):767–772. doi: 10.1038/bjc.1993.139. [DOI] [PMC free article] [PubMed] [Google Scholar]